Dinapsoline: Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease

Amit G. Gulwadi, Carolyn D. Korpinen, Richard Mailman, David E. Nichols, Sing Yuen Sit, Matthew T. Taber

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Dinapsoline is a new potent, full agonist at D1 dopamine receptors with limited selectivity relative to D2 receptors. The efficacy of this compound was assessed in rats with unilateral 6-hydroxydopamine lesions of the medial forebrain bundle, a standard rat model of Parkinson's disease. Dinapsoline produced robust contralateral rotation after either subcutaneous or oral administration. This rotational behavior was attenuated markedly by the D1 receptor antagonist SCH-23390, but not by the D2 receptor antagonist raclopride. During a chronic 14-day treatment period in which rats received dinapsoline either once or twice a day, dinapsoline did not produce tolerance (in fact, some sensitization of the rotational response was observed in one experiment). Because dinapsoline shows less D1:D2 selectivity in vitro than other D1 agonists, the contribution of D2 activity to tolerance was assessed. Chronic daily cotreatment with dinapsoline and raclopride did not enable the development of tolerance to chronic dinapsoline treatment. In contrast, when dinapsoline was administered by osmotic minipump, rapid tolerance was observed. To explore further the contribution of D1 and D2 receptors to tolerance, experiments were performed with the selective D1 agonist A-77636. Daily dosing with A-77636 rapidly produced complete tolerance, as previously observed, whereas coadministration of the D2 agonist quinpirole plus A-77636 failed to either delay or prevent tolerance. Taken together, these results indicate that the development of tolerance to D1 receptor agonists is influenced by the pattern of drug exposure but not by the D1:D2 selectivity of the agonist.

Original languageEnglish (US)
Pages (from-to)338-344
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume296
Issue number2
StatePublished - Feb 13 2001

Fingerprint

Dopamine Agonists
Parkinson Disease
A 77636
Raclopride
Medial Forebrain Bundle
Quinpirole
Dopamine D1 Receptors
dinapsoline
Oxidopamine
Oral Administration
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Gulwadi, Amit G. ; Korpinen, Carolyn D. ; Mailman, Richard ; Nichols, David E. ; Sit, Sing Yuen ; Taber, Matthew T. / Dinapsoline : Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. In: Journal of Pharmacology and Experimental Therapeutics. 2001 ; Vol. 296, No. 2. pp. 338-344.
@article{c93d22c994ed4fcb87c88602ee6cbd6c,
title = "Dinapsoline: Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease",
abstract = "Dinapsoline is a new potent, full agonist at D1 dopamine receptors with limited selectivity relative to D2 receptors. The efficacy of this compound was assessed in rats with unilateral 6-hydroxydopamine lesions of the medial forebrain bundle, a standard rat model of Parkinson's disease. Dinapsoline produced robust contralateral rotation after either subcutaneous or oral administration. This rotational behavior was attenuated markedly by the D1 receptor antagonist SCH-23390, but not by the D2 receptor antagonist raclopride. During a chronic 14-day treatment period in which rats received dinapsoline either once or twice a day, dinapsoline did not produce tolerance (in fact, some sensitization of the rotational response was observed in one experiment). Because dinapsoline shows less D1:D2 selectivity in vitro than other D1 agonists, the contribution of D2 activity to tolerance was assessed. Chronic daily cotreatment with dinapsoline and raclopride did not enable the development of tolerance to chronic dinapsoline treatment. In contrast, when dinapsoline was administered by osmotic minipump, rapid tolerance was observed. To explore further the contribution of D1 and D2 receptors to tolerance, experiments were performed with the selective D1 agonist A-77636. Daily dosing with A-77636 rapidly produced complete tolerance, as previously observed, whereas coadministration of the D2 agonist quinpirole plus A-77636 failed to either delay or prevent tolerance. Taken together, these results indicate that the development of tolerance to D1 receptor agonists is influenced by the pattern of drug exposure but not by the D1:D2 selectivity of the agonist.",
author = "Gulwadi, {Amit G.} and Korpinen, {Carolyn D.} and Richard Mailman and Nichols, {David E.} and Sit, {Sing Yuen} and Taber, {Matthew T.}",
year = "2001",
month = "2",
day = "13",
language = "English (US)",
volume = "296",
pages = "338--344",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

Dinapsoline : Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. / Gulwadi, Amit G.; Korpinen, Carolyn D.; Mailman, Richard; Nichols, David E.; Sit, Sing Yuen; Taber, Matthew T.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 296, No. 2, 13.02.2001, p. 338-344.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dinapsoline

T2 - Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease

AU - Gulwadi, Amit G.

AU - Korpinen, Carolyn D.

AU - Mailman, Richard

AU - Nichols, David E.

AU - Sit, Sing Yuen

AU - Taber, Matthew T.

PY - 2001/2/13

Y1 - 2001/2/13

N2 - Dinapsoline is a new potent, full agonist at D1 dopamine receptors with limited selectivity relative to D2 receptors. The efficacy of this compound was assessed in rats with unilateral 6-hydroxydopamine lesions of the medial forebrain bundle, a standard rat model of Parkinson's disease. Dinapsoline produced robust contralateral rotation after either subcutaneous or oral administration. This rotational behavior was attenuated markedly by the D1 receptor antagonist SCH-23390, but not by the D2 receptor antagonist raclopride. During a chronic 14-day treatment period in which rats received dinapsoline either once or twice a day, dinapsoline did not produce tolerance (in fact, some sensitization of the rotational response was observed in one experiment). Because dinapsoline shows less D1:D2 selectivity in vitro than other D1 agonists, the contribution of D2 activity to tolerance was assessed. Chronic daily cotreatment with dinapsoline and raclopride did not enable the development of tolerance to chronic dinapsoline treatment. In contrast, when dinapsoline was administered by osmotic minipump, rapid tolerance was observed. To explore further the contribution of D1 and D2 receptors to tolerance, experiments were performed with the selective D1 agonist A-77636. Daily dosing with A-77636 rapidly produced complete tolerance, as previously observed, whereas coadministration of the D2 agonist quinpirole plus A-77636 failed to either delay or prevent tolerance. Taken together, these results indicate that the development of tolerance to D1 receptor agonists is influenced by the pattern of drug exposure but not by the D1:D2 selectivity of the agonist.

AB - Dinapsoline is a new potent, full agonist at D1 dopamine receptors with limited selectivity relative to D2 receptors. The efficacy of this compound was assessed in rats with unilateral 6-hydroxydopamine lesions of the medial forebrain bundle, a standard rat model of Parkinson's disease. Dinapsoline produced robust contralateral rotation after either subcutaneous or oral administration. This rotational behavior was attenuated markedly by the D1 receptor antagonist SCH-23390, but not by the D2 receptor antagonist raclopride. During a chronic 14-day treatment period in which rats received dinapsoline either once or twice a day, dinapsoline did not produce tolerance (in fact, some sensitization of the rotational response was observed in one experiment). Because dinapsoline shows less D1:D2 selectivity in vitro than other D1 agonists, the contribution of D2 activity to tolerance was assessed. Chronic daily cotreatment with dinapsoline and raclopride did not enable the development of tolerance to chronic dinapsoline treatment. In contrast, when dinapsoline was administered by osmotic minipump, rapid tolerance was observed. To explore further the contribution of D1 and D2 receptors to tolerance, experiments were performed with the selective D1 agonist A-77636. Daily dosing with A-77636 rapidly produced complete tolerance, as previously observed, whereas coadministration of the D2 agonist quinpirole plus A-77636 failed to either delay or prevent tolerance. Taken together, these results indicate that the development of tolerance to D1 receptor agonists is influenced by the pattern of drug exposure but not by the D1:D2 selectivity of the agonist.

UR - http://www.scopus.com/inward/record.url?scp=0034746512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034746512&partnerID=8YFLogxK

M3 - Article

C2 - 11160615

AN - SCOPUS:0034746512

VL - 296

SP - 338

EP - 344

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -